Evaluation of antibodies to oxidized low-density lipoprotein and assessment of C-reactive protein in acute coronary syndrome and stable coronary artery disease

Summary

The aim was to measure the level of antibodies to oxidized LDL (oxLDL) and C-reactive protein (CRP) in the serum of patients with acute coronary syndrome (ACS). The results were correlated with data obtained from patients with stable coronary artery disease (stable CAD) and healthy controls.Thirty-three patients with ACS and 62 stable CAD patients were enrolled in the study. Fifty healthy individuals served as controls.The evaluation of anti-oxLDL autoantibodies was performed by ELISA, while CRP levels were measured by turbidimetry. The level of antibodies to oxLDL was significantly higher in both groups of patients with ACS and stable CAD compared to controls.The comparison between the acute and stable groups showed that anti-oxLDL levels were higher in the acute group,but because of high SD, the difference was not significant. By performing group analysis, anti-oxLDL levels were found to be significantly higher in ACS patients with unstable clinical state (circulatory insufficiency, malignant arrhythmias, recurring ischemic pain, need for urgent coronary intervention and death). CRP level in patients with ACS was significantly higher than in those with stable CAD. A positive correlation was found between anti-oxLDL antibodies and CRP levels both in patients with ACS and stable CAD. The association between the two biomarkers was stronger in the ACS group. In conclusion, our findings support the notion that the presence of antibodies to oxLDL, a plaquespecific antigen, plays a major role as a predictor of complicated manifestations of ACS.

Keywords

Atherosclerosis - coronary artery disease - antibodies to oxidized LDL - C-reactive protein

• References

• 1 Biasucci LM, Santamaria M, Liuzzo G. Inflammation, atherosclerosis and acute coronary syndrome. Minerva Cardioangiol 2002; 50: 475-486.
• 2 George J, Afek A, Gilburd B. et al. Induction of early atherosclerosis in LDL-receptor-deficient mice immunized with beta2-glycoprotein I. Circulation 1998; 98: 1108-1115.
• 3 Goon PK, Boos CJ, Stonelake PS. et al. Detection and quantification of mature circulating endothelial cells using flow cytometry and immunomagnetic beads: a methodological comparison. Thromb Haemost 2006; 96: 45-52.
• 4 Sherer Y, Shoenfeld Y. Immunomodulation for treatment and prevention of atherosclerosis. Auto-immun Rev 2002; 1: 21-27. Review.
• 5 Veres K, Lakos G, Kerényi A. et al. Antiphospholipid antibodies in acute coronary syndrome: implications for pathogenesis and prognosis. Lupus 2004; 13: 423-427.
• 6 Berliner JA, Subbanagounder G, Leitinger N. et al. Evidence for a role of phospholipid oxidation products in atherogenesis. Trends Cardiov Med 2001; 11: 142-147.
• 7 Parthasarathy S, Wieland E, Steinberg D. A role of endothelial cell lipoxygenase in the oxidative modification of low density lipoprotein. Proc Natl Acad Sci USA 1989; 86: 1046-1050.
• 8 Wu R, Nityanand S, Berglund L. et al. Antibodies against cardiolipin and oxidatively modified LDL in 50-year-old men predict myocardial infarction. Arterioscler Thromb Vasc Biol 1997; 17: 3159-3163.
• 9 Salonen JT, Yla Herttuala S, Yamamoto R. et al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 1992; 339: 883-887.
• 10 George J, Ahmed A, Patnaik M. et al. The prediction of coronary atherosclerosis employing artificial neural networks. Clin Cardiol 2000; 23: 453-456.
• 11 George J, Harats D, Bakshi E. et al. Anti-oxidized low density lipoprotein antibody determination as a predictor of restenosis following percutaneous transluminal coronary angioplasty. Immunol Lett 1999; 68: 263-266.
• 12 Miyakis S, Lockshin MD, Atsumi T. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome(APS). J Thromb Haemost 2006; 4: 295-306.
• 13 Vaarala O. Antibodies to oxidised LDL. Lupus 2000; 9: 202-205.
• 14 Hasunuma Y, Matsuura E, Makita Z. et al. Involvement of beta 2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin Exp Immunol 1997; 107: 569-573.
• 15 Tuomisto K, Jousilahti P, Sundvall J. et al. C-reactive protein, interleukin-6 and tumor necrosis factor alpha as predictors of incident coronary and cardiovascular events and total mortality. A population-based, prospective study. Thromb Haemost 2006; 95: 511-518.
• 16 De Maria AN, Ben-Yehuda O, Berman D. et al. Highlights of the Year in JACC 2003. J Am Coll Cardiol 2003; 42: 2156-2166.
• 17 Ikonomidis I, Lekakis J, Kremastinos DT. Inflammatory markers for risk stratification in primary prevention of cardiovascular disease: time for a “multi-marker” approach?. Thromb Haemost 2006; 95: 397-398.
• 18 Labarrere CA, Zaloga GP. C-reactive protein: from innocent bystander to pivotal mediator of atherosclerosis. Am J Med 2004; 117: 499-507.
• 19 Stemme S, Faber B, Holm J. et al. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci 1995; 92: 3893-3897.
• 20 Shoenfeld Y, Wu R, Dearing L. et al. Are anti-oxidized low-density lipoprote in antibodies pathogenic or protective?. Circulation 2004; 110: 2552-2558.
• 21 George J, Afek A, Gilburd B. et al. Hyperimmunization of apo-E-deficient mice with homologous malondialdehyde low-density lipoprotein suppresses early atherogenesis. Atherosclerosis 1998; 138: 147-152.
• 22 Caligiuri G, Nicoletti A, Poirier B. et al. Protective immunity against atherosclerosis carried by Bcells of hypercholesterolemic mice. J Clin Invest 2002; 109: 745-753.
• 23 Shoji T, Nishizawa Y, Fukumoto M. et al. Inverse relationship between circulating oxidized low density lipoprotein(oxLDL) andanti-oxLDL antibody levels in healthy subjects. Atherosclerosis 2000; 148: 171-177.
• 24 Fukumoto M, Shoji T, Emoto M. et al. Antibodies against oxidized LDL and carotidarteryintima-media thickness in a healthy population. Arterioscler Thromb Vasc Biol 2000; 20: 703-707.
• 25 Ylä-Herttuala S, Palinski W, Butler SW. et al. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler Thromb 1994; 14: 32-40.
• 26 Bergmark C, Wu R, de Faire U. et al. Patients with early-onset peripheral vascular disease have increased levels of autoantibodies against oxidized LDL. Arterioscler Thromb Vasc Biol 1995; 15: 441-445.
• 27 Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-874.
• 28 Wu R, Lefvert AK. Autoantibodies against oxidized low density lipoproteins (oxLDL): characterization of antibody isotope, subclass, affinity and effect on the macrophage uptake of oxLDL. Clin Exp Immunol 1995; 102: 174-180.
• 29 Virella G, Atchley D, Koskinen S. et al. Proatherogenic and proinflammatory properties of immune complexes prepared with purified human oxLDL antibodies and human oxLDL. Clin Immunol 2002; 105: 81-92.
• 30 Ameli S, Hultgardh-Nilsson A, Regnstrom J. et al. Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. Arterioscler Thromb Vasc Biol 1996; 16: 1074-1079.
• 31 Vaarala O, Puurunen M, Manttari M. et al. Antibodies to prothrombin imply a risk of myocardial infarction in middle-aged men. Thromb Haemost 1996; 75: 456-459.
• 32 Vaarala O. Antiphospholipid antibodies and atherosclerosis. Lupus 1996; 5: 442-447. Review.
• 33 Auer J, Berent R, Lassing E. et al. C-reactive protein and coronary artery disease. Jpn Heart J 2002; 43: 607-619.
• 34 Mirat J, Raguz M, Romic Z. et al. Inflammation markers in acute coronary syndrome. Acta Med Croatica 2004; 58: 115-117.
• 35 Szodoray P, Timar O, Veres K. et al. Th1/Th2 imbalance, measured by circulating and intracytoplasmic inflammatory cytokines- immunological alterations in acute coronary syndrome and stable coronary artery disease. Scand J Immunol 2006; 64: 336-344.